Senseonics In-House Eversense Rollout Lifts 2025 Revenue to $35.3M, Guides 65–76% Growth
Senseonics ended 2025 with $35.3 million in revenue and gross margins exceeding 50% after transitioning Eversense commercialization back in-house and doubling U.S. patient starts to 103%. For 2026 the company guides $58–62 million in sales, 65–76% growth, while planning $150–160 million in operating expenses and $110–120 million cash burn.
1. Strategic Transition Back In-House
Senseonics shifted global Eversense commercialization from Ascensia back to its own operations, securing full operational control and eliminating revenue sharing. PHC remains a key shareholder supporting European commercialization under transitional service agreements, with in-country operations expected to close in the second quarter.
2. 2025 Financial Performance
Full-year 2025 revenue reached $35.3 million, up from $22.5 million in 2024, with gross margins above 50%. Fourth-quarter net revenue rose 72% to $14.3 million, while net loss widened to $20.8 million on higher SG&A spending.
3. 2026 Outlook and Guidance
The company projects 2026 revenue of $58–62 million, reflecting 65–76% growth, with gross margins above 50%. It plans $150–160 million in operating expenses, $110–120 million in cash use and an expanded $100 million debt facility, and anticipates Europe will represent about 20% of sales.
4. Commercial Execution and Patient Growth
Senseonics doubled U.S. patient starts to 103% year-over-year, expanded its EonCare inserter network toward 100 providers and increased active prescribers by over 80%. It will invest $12–15 million in direct-to-consumer marketing and leverage integration with Sequel’s twiist AID system to drive adoption and retention.